TheEdgeResearch
Home / Stocks / LQDA

Liquidia Corporation (LQDA)

NASDAQ Healthcare Medical - Pharmaceuticals
$54.43 ▼ -3.88%
Market Cap
$4.90B
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.54
52-Wk Range
22.31-93.61
CEO
Roger A. Jeffs
Country
US
Currency
USD

Liquidia Corporation operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Morrisville, NC, US. The stock last traded at $54.43, down 3.88% on the session, giving a market capitalisation of $4.90B. On trailing twelve-month figures it carries a trailing P/E of -52.84, a net margin of -15.1%. Its beta of 0.54 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-52.84
Price / Sales
7.89
Price / Book
-191.58
EV / EBITDA
-52.53
Gross margin
92.7%
Operating margin
-15.6%
Net margin
-15.1%
Return on equity
—
Debt / equity
-6.64
Current ratio
1.02
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
216
IPO date
2018-07-26
Headquarters
Morrisville, NC, US
About Liquidia Corporation

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Comparable companies

Liquidia Corporation is most often compared with the following Healthcare names:

AVLNINSMUTHRVCRE
More research on LQDA
LQDA technical analysis LQDA TheEdge Score Compare against peers
Open full interactive analysis & DCF →